Theranostics Australia will be hosting a breakfast session tomorrow at the #WFNMB2018 Conference – “Next Generation Theranostics”. We are thrilled to have Prof Dale Bailey, Prof Kate Vallis, Dr Matt Harris and Dr Danielle Meyrick speaking about the future of theranostics.
National Operations Manager, Ms Julie Crouch, is presenting at the #WFNMB2018 conference within the ANZSNM Technologist SIG session
Theranostics Australia’s Ms Julie Crouch (National Operations Manager) will be presenting today at the #WFNMB2018 conference within the ANZSNM Technologist SIG session – “The Optimum Protocol for Ga-68 PSMA Within a Private Practice”. Best of luck to all the speakers involved.
Theranostics Australia is proud to be a Supporting Partner of the 12th World Congress of the World Federation of Nuclear Medicine & Biology in Melbourne, April 20 – 24 2018 >> https://goo.gl/RaJBas
Theranostics Australia’s A/Prof Nat Lenzo will be presenting at Perth Urology Clinic’s GP Urology Masterclass on “theranostics” as a non-surgical cancer therapy. A/Prof Lenzo joins speakers from Perth Urological Clinic, Perth Radiology Clinic, Oncology West and GenesisCare. Topics include: female urology and OAB, urological stone disease, surgical andrology, male LUTS and BPH, urological oncology and non-surgical cancer therapy.
SCHOLARSHIP OPPORTUNITY: Telix Pharmaceuticals has partnered with Memorial Sloan Kettering Cancer Centre (MSKCC) to create a fully-funded place for an Australian undergraduate* to attend the Molecular Imaging Summer Program (MISP) in New York. (*subject to specific criteria). Read More/Apply here >> https://goo.gl/VX2BR4 **Applications can be sent directly to email@example.com up until the (extended) deadline of Feb 9th.**
Novartis AG (NVS) announced that Advanced Accelerator Applications (AAA), a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approval of its new drug application or NDA for Lutathera, a treatment for somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), in adults. Read More>> https://goo.gl/AChzVF & https://goo.gl/kgZYSL
Christmas Closure: Theranostics Australia will be closed from the 23rd of December 2017 and will reopen on Monday 8th of January 2018.
Advanced Accelerator Applications S.A. (AAA) announced in AUG17 that the Food and Drug Administration (FDA), in the United States, has accepted and considered complete the resubmission of the New Drug Application (NDA) for its investigational drug lutetium Lu 177 dotatate (Lutathera). Lutathera is the brand name for the radiologic used in Peptide Receptor Radionuclide Therapy (PRRT). The FDA has set an action date of Jan 26, 2018. Read more >>> https://goo.gl/sjURwh (2/2)
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended eleven medicines for approval at its July 2017 meeting. This included Lutathera (lutetium [177Lu] oxodotreotide), an orphan drug for the treatment of well differentiated gastro-entero-pancreatic neuroendocrine tumours. (1/2) Read More >> https://goo.gl/cRrRpb
The OPS-201 trial has now commenced in Perth. This IPSEN sponsored trial involves the use of Lutetium-177 OPS-201 for treatment of progressive metastatic neuroendocrine tumours (NETs). Theranostics Australia is one of several sites worldwide currently recruiting (together with Peter Mac in Melbourne, Royal Free in London and Memorial Sloan Kettering in New York).
This agent binds to both activated and unactivated somatostatin receptors which are upregulated on these tumours. There is far higher binding via this mechanism than standard octreotate.
The protocol involves 3 cycles 8 weeks apart of intravenous Lu-177 OPS-201. All patients will have baseline Ga-68 octreotate imaging performed.
The treatment is available for all NET patients with progressive metastatic disease including gastric and pancreatic NETs, pulmonary carcinoids, paraganglionomas and phaeochromacytomas.
Patients who have previously had Lu-177 octreotate are not eligible. Patients may have had any other treatment including chemotherapy, radiotherapy or SSTR analogues.
Costs of all tests, treatment and follow up is covered by Ipsen. The study is open to all patients – public or private.
If you would like further information on the trial or would like to refer a patient for screening assessment please contact us via email: firstname.lastname@example.org or phone: +61 8 9091 1081.